CRXT - Antares resubmitted NDA for testosterone replacement therapy Tlando accepted by FDA

The FDA has accepted a New Drug Application for the oral testosterone replacement therapy ("TRT") Tlando from Antares Pharma (NYSE:ATR). The new action date is March 28. Tlando was granted tentative approval as a twice daily treatment. Previously, the FDA determined that Tlando met efficacy and safety standards and will be eligible for final approval following the expiration of exclusivity for Clarus Therapeutics' (NASDAQ:CRXT) Jatenzo TRT on March 27. Read why Seeking Alpha contributor Andy Jones views Antares as a buy.

For further details see:

Antares resubmitted NDA for testosterone replacement therapy Tlando accepted by FDA